Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

January 20 – 26, 2025

Pα+ Psychedelic Bulletin 186

Psychedelic Alpha ↗

  • As Trump Takes Office, Impact on Psychedelics Field Remains Unclear
    • Psychedelics Advocate Sergey Brin Bags Seat in Billionaire’s Gallery
    • When MAHA?
    • NIH Freeze Stokes Funding Fears; Might Psychedelics Benefit?
  • Psychedelic Power Couple, the Jurvetsons, Talk Trump, Lykos, and Philanthropy at Munich Conference
    • Genevieve Jurvetson Hopes to Get MDMA Approved This Year
  • J&J Buys Intra-Cellular for $14.6 Billion
  • Lykos Provides Update on Board Departures, FDA Meeting, and U.S. Patent Applications
  • GH Research Shares Positive Results from Proof of Concept Studies; Provides Update on FDA Clinical Hold
  • and more…

January 13 – 19, 2025

HELP WANTED

↗

Psychedelic Alpha is looking for someone to help us share our content on social media and other platforms. The right person is familiar with the psychedelics field, is able to summarise our content and pull out key themes or quotes, and has graphic design skills. If you are interested in this position, please contact hello@psychedelicalpha.com with one or two sentences about yourself and any samples of your work.

January 6 – 12, 2025

Pα+ Psychedelic Bulletin #185

Psychedelic Alpha ↗

  • Joe Rogan on Ibogaine: Rick Perry and Bryan Hubbard Appear in Two-Hour Interview
  • On Psychedelic Lobbying (Otsuka Joins In)
  • Neumora’s Kappa Opioid Receptor Drug for Depression Fails in Phase 3
  • Wisconsin’s Medicaid System to Cover IV Ketamine for Major Depressive Disorder
  • Inside the Plan to Make Lykos MAPS Again
    Other Stories
  • Tacoma Set to Vote on Psychedelic Decrim.
  • APA Special Issue, APA Workshops and Webinars
  • Colorado Regulator’s Last-Minute Changes
  • and more…

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Psychedelic Alpha ↗

This latest twist in the Lykos Therapeutics saga threatens a major overhaul of the company’s strategy and direction, with Musk ally and billionaire investor Antonio Gracias appearing to want to take the company back toward its nonprofit drug development roots and a more Doblinite philosophy. Now, the company’s board must decide whether to stick with its current lead investor, Helena, or accept Gracias’ proposal.

December 30, 2024 – January 5, 2025

Pα+ Psychedelic Bulletin #184

Psychedelic Alpha ↗

  • We explore psychedelics-related lobbying activity at the federal level in Q3’24, which saw a significant increase in such efforts
  • Psychoplastogens a ‘primary focal point’ of depression trials last year
  • NJ Psilocybin Bill Appears Dead
  • FDA moves to restrict Amanita muscaria
  • DEA increases DMT production quota
  • and more…

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.